MENU

Confirmed Exhibitors

Stay in the Know
Get the latest news on exciting speakers, workshops & learning opportunities at ICNMD 2022.

Subscribe for Updates

ICNMD 2022 is an excellent opportunity to interact with a diverse group of clinicians, scientists, students, and industry professionals involved with muscular dystrophies, other myopathies, myasthenia gravis, polyneuropathies, spinal cord disorders, and neurofibromatosis, to list only a few.

ICNMD 2022 would like to thank the following companies for their support:

EXHIBITORS

Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina. (astellasgenetherapies.com) 

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases and cancers by translating immunology breakthroughs into potential new medicines. argenx has offices in Belgium, the United States, Japan and Switzerland. Visit us at www.argenx.com. Follow us on LinkedIn.

At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp. Today, Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, neuropsychiatry, immunology, acute neurology, and neuropathic pain. (biogen.com)

Lupin Neurosciences is a Specialty Pharma Division of Lupin. We are committed to improving the lives of patients affected by underserved neurological disorders. Our mission is to expand patient access to science-based therapies and solutions through building a global portfolio of speciality pharmaceuticals for development, registration and commercialization with partners and collaborators. Lupin Neurosciences is headquartered in Zug, Switzerland due to its favourable business environment and strong pool of candidates with the specialty pharma expertise needed to support the division’s current and future activities. The division’s initial focus is to identify treatment solutions within the neuromuscular and movement disorder areas, and aims to broaden, over time, its focus to other therapy areas within the neuroscience field. (lupin.com) 

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Facebook, LinkedIn, Twitter and Instagram.

At Sarepta, we are working with urgency to develop breakthrough therapies to treat genetic diseases. Currently, we have more than 40 investigational therapies in various stages of development—many already in late-stage clinical trials. For more information, please visit our website at https://www.sarepta.com.

  

Scholar Rock, Inc. is a clinical stage biopharmaceutical company focused on discovery and development of innovative medicines for the treatment of serious diseases.  Please join us at our booth or virtually at www.scholarrock.com to learn more about Scholar Rock, our pipeline and the importance of myostatin in Spinal Muscular Atrophy.

SERB specialty pharmaceuticals is bringing lifesaving drugs that meet high unmet medical needs. SERB has extended its Rare Diseases portfolio in both Neurology (with treatments for severe epileptic and Lambert Eaton Myasthenic Syndrome) and Metabolic Disorders. Serb makes available the only EMA registered drug for symptomatic treatment of adult LEMS patients. (serb.eu)

  




Stay Up to Date!
Receive the latest information about the International Congress on Neuromuscular Diseases by entering your information below.
X